GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Xvivo Perfusion AB (STU:3XV) » Definitions » EV-to-FCF

Xvivo Perfusion AB (STU:3XV) EV-to-FCF : 185.08 (As of Apr. 27, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Xvivo Perfusion AB EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Xvivo Perfusion AB's Enterprise Value is €964.65 Mil. Xvivo Perfusion AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was €5.21 Mil. Therefore, Xvivo Perfusion AB's EV-to-FCF for today is 185.08.

The historical rank and industry rank for Xvivo Perfusion AB's EV-to-FCF or its related term are showing as below:

STU:3XV' s EV-to-FCF Range Over the Past 10 Years
Min: -1975.32   Med: 113.33   Max: 3532
Current: 178.25

During the past 12 years, the highest EV-to-FCF of Xvivo Perfusion AB was 3532.00. The lowest was -1975.32. And the median was 113.33.

STU:3XV's EV-to-FCF is ranked worse than
93.22% of 369 companies
in the Medical Devices & Instruments industry
Industry Median: 26.55 vs STU:3XV: 178.25

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-27), Xvivo Perfusion AB's stock price is €31.50. Xvivo Perfusion AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €0.296. Therefore, Xvivo Perfusion AB's PE Ratio for today is 106.42.


Xvivo Perfusion AB EV-to-FCF Historical Data

The historical data trend for Xvivo Perfusion AB's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xvivo Perfusion AB EV-to-FCF Chart

Xvivo Perfusion AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -80.62 -112.69 -73.70 -50.66 -101.02

Xvivo Perfusion AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 297.63 212.23 161.72 -101.02 135.68

Competitive Comparison of Xvivo Perfusion AB's EV-to-FCF

For the Medical Devices subindustry, Xvivo Perfusion AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xvivo Perfusion AB's EV-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Xvivo Perfusion AB's EV-to-FCF falls into.



Xvivo Perfusion AB EV-to-FCF Calculation

Xvivo Perfusion AB's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=964.647/5.212
=185.08

Xvivo Perfusion AB's current Enterprise Value is €964.65 Mil.
Xvivo Perfusion AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €5.21 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Xvivo Perfusion AB  (STU:3XV) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Xvivo Perfusion AB's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=31.50/0.296
=106.42

Xvivo Perfusion AB's share price for today is €31.50.
Xvivo Perfusion AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.296.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Xvivo Perfusion AB EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Xvivo Perfusion AB's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Xvivo Perfusion AB (STU:3XV) Business Description

Traded in Other Exchanges
Address
Massans gata 10, P.O. Box 53015, Gothenburg, SWE, SE-400 14
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of all major organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments namely, Thoracic: Sales of lung and heart transplant products, Abdominal: Sales of liver and kidney transplant products. Services: Revenue from sales of services in organ recovery (carried out by subsidiary STAR Teams Inc.). The majority of revenue is derived from the Thoracic segment. Geographically, the majority is from the United States.

Xvivo Perfusion AB (STU:3XV) Headlines

No Headlines